Updates in the new AHA/ACC/HFSA heart failure guideline - PACE-CME

Updates in the new AHAACCHFSA heart failure guideline

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Effects of a myeloperoxidase inhibitor in patients with HFpEF
Effects of a myeloperoxidase inhibitor in patients with HFpEF
AHA 2024
Effects of a myeloperoxidase inhibitor in patients with HFpEF
- Sanjiv Shah, MD
Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
AHA 2024
Acoramidis reduces all-cause mortality in ATTR-CM
- Daniel Judge, MD
Audit and feedback strategy for pharmacists improves HF care
Audit and feedback strategy for pharmacists improves HF care
AHA 2024
Audit and feedback strategy for pharmacists improves HF care
- Alexander Sandhu, MD
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
MinuteCE®
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
1.25 program credits
- Akshay S. Desai, MD
- John McMurray, MD
1.25 program credits